SCHEMBL30278500

SCHEMBL30278500

FC(F)(F)Oc1cccc(C#Cc2cccnc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.56
NPY5R Q15761 1/20 0.49
FFAR1 O14842 1/20 0.49
HAO1 Q9UJM8 1/20 0.47
GRM2 Q14416 2/20 0.44
KCNH2 Q12809 2/20 0.44
DYRK1A Q13627 2/20 0.44
KCNA5 P22460 1/20 0.44
CYP2A6 P11509 3/20 0.43
CYP2E1 P05181 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2B6 P20813 2/20 0.41
CYP2C19 P33261 2/20 0.41
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1476671 0.81 GRM5 (0.50) GRM5FFAR1
Hydrochloric Acid SCHEMBL1476841 0.78 GRM5 (0.54) GRM5HAO1KCNH2CYP2A6CYP2E1
SCHEMBL30278437 0.78 GRM5 (0.59) GRM5FFAR1HAO1
SCHEMBL12135612 0.77 ADORA1 (0.47) GRM5NPY5RKCNH2DYRK1AKCNA5
SCHEMBL30562384 0.76 NPY5R (0.67) NPY5RKCNH2DYRK1AKCNA5CYP2A6
SCHEMBL9679235 0.76 GRM5 (0.53) GRM5FFAR1CYP3A4RAB9A
SCHEMBL13362351 0.76 NPY5R (0.67) NPY5RKCNH2DYRK1AKCNA5CYP2A6
SCHEMBL2303193 0.76 NPC1 (0.51) NPY5RGRM2KCNH2DYRK1AKCNA5
SCHEMBL29497468 0.76 NPC1 (0.51) NPY5RGRM2KCNH2DYRK1AKCNA5
SCHEMBL30963881 0.76 CYP19A1 (0.50) GRM5HAO1KCNH2CYP2A6CYP2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376452-A1 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof ENANTA PHARM INC (US) 2025-12-11 US disclosed
US-12384753-B2 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2025-08-12 US disclosed
EP-4387603-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF Enanta Pharmaceuticals, Inc. (US) 2024-06-26 EP disclosed
CN-118103038-A 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof 英安塔制药有限公司 2024-05-28 CN disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 GRM5 2220/4885NPY5R 2371/4885FFAR1 1081/4885
US-20250376452-A1 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof HSD17B1, HSD17B13, HSD17B3 GRM5 2220/4885NPY5R 2371/4885FFAR1 1081/4885
US-12384753-B2 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof HSD17B1, HSD17B13, HSD17B3 GRM5 2220/4885NPY5R 2371/4885FFAR1 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.